Related Experiment Video
Updated: Dec 29, 2025
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
Published on: February 3, 2023
TGF-β2 silencing to target biliary-derived liver diseases
Anne Dropmann1, Steven Dooley2, Bedair Dewidar1,3
1Molecular Hepatology-Alcohol Associated Diseases, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Objective:
TGF-β2 (TGF-β, transforming growth factor beta), the less-investigated sibling of TGF-β1, is deregulated in rodent and human liver diseases. Former data from bile duct ligated and MDR2 knockout (KO) mouse models for human cholestatic liver disease suggested an involvement of TGF-β2 in biliary-derived liver diseases.
Design:
As we also found upregulated TGFB2 in liver tissue of patients with primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), we now fathomed the positive prospects of targeting TGF-β2 in early stage biliary liver disease using the MDR2-KO mice. Specifically, the influence of TgfB2 silencing on the fibrotic and inflammatory niche was analysed on molecular, cellular and tissue levels.
Results:
TgfB2-induced expression of fibrotic genes in cholangiocytes and hepatic stellate cellswas detected. TgfB2 expression in MDR2-KO mice was blunted using TgfB2-directed antisense oligonucleotides (AON). Upon AON treatment, reduced collagen deposition, hydroxyproline content and αSMA expression as well as induced PparG expression reflected a significant reduction of fibrogenesis without adverse effects on healthy livers. Expression analyses of fibrotic and inflammatory genes revealed AON-specific regulatory effects on Ccl3, Ccl4, Ccl5, Mki67 and Notch3 expression. Further, AON treatment of MDR2-KO mice increased tissue infiltration by F4/80-positive cells including eosinophils, whereas the number of CD45-positive inflammatory cells decreased. In line, TGFB2 and CD45 expression correlated positively in PSC/PBC patients and localised in similar areas of the diseased liver tissue.
Conclusions:
Taken together, our data suggest a new mechanistic explanation for amelioration of fibrogenesis by TGF-β2 silencing and provide a direct rationale for TGF-β2-directed drug development.
Insights
Transforming growth factor beta 2 (TGF-β2) silencing ameliorates liver fibrosis in a mouse model of cholestatic liver disease. Targeting TGF-β2 offers a promising therapeutic strategy for early-stage biliary liver diseases like PSC and PBC.
Area of Science:
- Hepatology and Immunology
- Molecular Biology and Genetics
Background:
- Transforming growth factor beta 2 (TGF-β2) is deregulated in rodent and human liver diseases, particularly cholestatic conditions.
- Previous studies suggested TGF-β2 involvement in biliary-derived liver diseases.
- Upregulated TGFB2 expression was observed in liver tissue of patients with primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).
Purpose of the Study:
- To investigate the therapeutic potential of targeting TGF-β2 in early-stage biliary liver disease.
- To analyze the effects of TGF-β2 silencing on the fibrotic and inflammatory niche in a mouse model.
Main Methods:
- Utilized MDR2 knockout (KO) mice, a model for human cholestatic liver disease.
- Administered TGF-β2-directed antisense oligonucleotides (AON) to blunt TGF-β2 expression in MDR2-KO mice.
- Analyzed molecular, cellular, and tissue-level changes related to fibrosis and inflammation.
Main Results:
- TGF-β2 silencing significantly reduced collagen deposition, hydroxyproline content, and alpha-smooth muscle actin (αSMA) expression, indicating reduced fibrogenesis.
- AON treatment led to induced PPAR-gamma (PparG) expression without adverse effects on healthy livers.
- Gene expression analysis revealed AON-specific regulatory effects on inflammatory markers (Ccl3, Ccl4, Ccl5, Mki67, Notch3).
- TGF-β2 silencing modulated immune cell infiltration, decreasing CD45+ cells while increasing F4/80+ cells (including eosinophils).
- A positive correlation between TGFB2 and CD45 expression was found in PSC/PBC patients.
Conclusions:
- TGF-β2 silencing effectively ameliorates liver fibrogenesis in a cholestatic liver disease model.
- The study provides a mechanistic explanation for TGF-β2's role in liver fibrosis.
- These findings support TGF-β2 as a direct therapeutic target for drug development in biliary liver diseases.
